Article info
How to do it
CSF biomarkers for dementia
- Correspondence to Professor Jonathan M Schott, Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK; j.schott{at}ucl.ac.uk
Citation
CSF biomarkers for dementia
Publication history
- Accepted February 18, 2022
- First published March 17, 2022.
Online issue publication
October 18, 2023
Article Versions
- Previous version (18 October 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Neurofilament light chain as a biomarker in neurological disorders
- Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers
- Neuropathology and emerging biomarkers in corticobasal syndrome
- Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia
- Biomarkers in dementia: clinical utility and new directions
- A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
- Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid
- Amyloid PET imaging in clinical practice
- Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias
- Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum